Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Immuneering Corp (IMRX)

Immuneering Q2 net loss widens to $17.3 million; cash falls to $182.7 million

Negative Impact 3 of 5 earnings Written later

Immuneering reported a second-quarter 2026 net loss of $17.3 million, or $0.27 per share, up from $14.4 million, or $0.40 per share, a year earlier. Cash, cash equivalents and marketable securities fell to $182.7 million at June 30, 2026 from $217.0 million at December 31, 2025, and the company says that cash is expected to fund operations into 2029.

Key points

  • Net loss was $17.3 million ($0.27 per share) for Q2 2026, compared with $14.4 million ($0.40 per share) for Q2 2025.
  • R&D expenses rose to $14.0 million from $10.5 million, mainly due to increased clinical costs for the atebimetinib program.
  • Cash and marketable securities were $182.7 million at June 30, 2026, versus $217.0 million at December 31, 2025.
  • Topline data from the Phase 3 MAPKeeper 301 trial is expected in mid-2028.

The filing

CompanyImmuneering Corp (IMRX)
Form8-K, current report
Filed with the SECAug 5, 2026, 7:41 AM ET
Accession number0001790340-26-000088

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.